🇺🇸 FDA
Pipeline program

ACE393

ACE393-103

Phase 2 mab active

Quick answer

ACE393 for Campylobacter Infection is a Phase 2 program (mab) at Fulcrum Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Fulcrum Therapeutics
Indication
Campylobacter Infection
Phase
Phase 2
Modality
mab
Status
active

Clinical trials